Menus Subscribe Search

Follow us


vaccine-diplomacy

(PHOTO: ALEXANDER RATHS/SHUTTERSTOCK)

Next Steps in U.S.-Iran Diplomacy: Vaccines

• November 06, 2013 • 11:00 AM

(PHOTO: ALEXANDER RATHS/SHUTTERSTOCK)

Two vaccine scientists—one American, one Iranian—offer a unique way to give the nascent relationship between their two countries a shot in the arm.

September’s historic dialogue between President Obama and Iran’s President Rouhani together with calls to seek constructive engagement opens the door to a little known but powerful foreign policy instrument, which could simultaneously create new life-saving vaccines.

The cornerstone of vaccine diplomacy is two or more countries putting aside their ideological differences to engage in an intense and focused scientific collaboration and produce an urgently needed technology that serves humanity.

In modern times, the first triumph of vaccine diplomacy occurred in the decade that began following the death of Stalin in 1953. Together, Dr. Albert B. Sabin in the U.S. and his Soviet virology counterpart each received back channel permission to jointly develop and then test a prototype oral polio vaccine on more than 10 million children in the USSR. The successful results led to the licensure of the oral polio vaccine in 1962, the elimination of polio in the U.S. in 1979, and ultimately the eradication of polio in all but three countries. Similar international cooperation with the Soviets to improve the vaccine was a key step resulting in the global eradication of smallpox.

Both the U.S. and Iran are under serious threat from several neglected tropical diseases that have emerged in our countries because of a variety of factors, including extreme poverty, urbanization, population growth, and possibly climate change.

Today, both the U.S. and Iran are under serious threat from several neglected tropical diseases that have emerged in our countries because of a variety of factors, including extreme poverty, urbanization, population growth, and possibly climate change. They include dengue fever, a mosquito-transmitted viral infection that results in hemorrhage, shock, and death. Dengue has recently emerged on the U.S. Gulf Coast and in southeastern Iran neighboring Pakistan. Kinetoplastid infections such as Chagas disease, a cause of severe heart disease, are now widespread among the poor in Texas and the southern U.S. where over 300,000 cases occur, while leishmaniasis, a severely disfiguring skin disease, affects 100,000 or more Iranians, and has also emerged in Texas and Oklahoma. Worm infections are still commonly found in impoverished areas in both countries, and where infections overall account for a significant amount of the health care burdens.

Both the U.S. and Iran would benefit enormously from research leading to the development and joint testing of vaccines against these neglected tropical diseases. Our recent investigations reveal that the extreme poor living in middle income and wealthy countries suffer as much from these conditions as those in the poorest countries in Africa, so that all of the world’s people living in poverty would benefit from new vaccines. Unfortunately because there is no major commercial market for neglected tropical disease vaccines (with the exception of dengue) the multinational pharmaceutical companies are not attempting to produce them.

In Iran, both fundamental and epidemiological research is conducted on a number of neglected tropical diseases including Crimean-Congo hemorrhagic fever, West Nile virus infection, brucellosis, leptospirosis, echinococcosis, fascioliasis, and intestinal worms. Iranian scientists have made several attempts at vaccines for some of their tropical infections, including prototype leishmaniasis vaccines made from live or killed whole parasites. However the efficacy and safety of such vaccines has thwarted further development along those lines. Nascent efforts to develop a safer and more effective vaccine through advanced genetic engineering—so called recombinant vaccines—are beginning, but a U.S. collaboration to accelerate their development will be needed. In addition, in order to enhance the efficacy of a recombinant leishmaniasis vaccine there may be requirements to add novel substances that increase the body’s immune response, but the best of these immunostimulants are currently only available in the West and can’t easily (or possibly legally) be shipped to Iran. Ultimately such steps would help to ensure future success in terms of producing a vaccine that would be widely used in the Middle East and adjoining regions of North Africa and Central Asia.

Indeed, such vaccines could be developed in the non-profit sector through joint activities of U.S.-based product development partnerships through support of the Gates Foundation, the National Institutes of Health, and other sources, together with Iranian institutions, such as the Tehran University and the Razi Serum and Vaccine Institute. However, meaningful scientific collaboration to actually produce such products is not currently practical given both financial and political constraints, including the need to overcome fears of potentially producing so-called “dual use” technologies. Therefore, high-level discussions need to first take place between the U.S. Department of State and its Iranian counterpart to actively encourage and support joint vaccine development, and then implement steps to effectively shape policy and launch the first stages of vaccine product development, including antigen discovery, process development, pilot manufacture, regulatory filing, and initial clinical testing.

Vaccine diplomacy’s modern day track record is impressive, having led to the global eradication of smallpox and the near-elimination of polio. It occurred because the U.S. and USSR put aside their differences during the Cold War. We now have an opening and potential path to do the same between the U.S. and Iran.

Peter Hotez and Mohammad Rokni
Peter Hotez is president of the Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development; dean of the National School of Tropical Medicine, Baylor College of Medicine; and Baker Institute Fellow in Disease and Poverty. Mohammad B. Rokni is professor of Medical Parasitology and Mycology in the School of Public Health at the Tehran University of Medical Sciences.

A weekly roundup of the best of Pacific Standard and PSmag.com, delivered straight to your inbox.

Recent Posts

October 1 • 2:00 PM

Most People With Addiction Simply Grow Out of It. Why Is This Widely Denied?

The idea that addiction is typically a chronic, progressive disease that requires treatment is false, the evidence shows. Yet the “aging out” experience of the majority is ignored by treatment providers and journalists.


October 1 • 1:00 PM

Midlife Neuroticism Linked to Alzheimer’s Disease in Old Age

New research from Sweden suggests that the personality dimension is connected to who ultimately suffers from late-in-life dementia.



October 1 • 11:11 AM

The Creative Class Boondoggle in Downtown Las Vegas

On Tony Hsieh and the pseudoscience of “collisions.”


October 1 • 9:14 AM

Mysterious Resting State Networks Might Be What Allow Different Brain Therapies to Work

Deep brain stimulation and similar treatments target the hubs of larger resting-state networks in the brain, researchers find.


October 1 • 6:00 AM

Would You Like a Subscription With Your Coffee?

A new app hopes to unite local coffee shops while helping you find a cheap cup of good coffee.


October 1 • 4:00 AM

How to Plant a Library

Somewhere outside of Oslo, there are 1,000 newly planted spruce trees. One hundred years from now, if everything goes to plan, they’ll be published together as 100 pieces of art.



September 30 • 10:09 AM

Trust Is Waning, and Inequality May Be to Blame

Trust in others and confidence in institutions is declining, while economic inequality creeps up, a new study shows.


September 30 • 8:00 AM

The Psychology of Penmanship

Graphology: It’s all (probably) bunk.



September 30 • 6:00 AM

The Medium Is the Message, 50 Years Later

Five decades on, what can Marshall McLuhan’s Understanding Media tell us about today?


September 30 • 4:00 AM

Grad School’s Mental Health Problem

Navigating the emotional stress of doctoral programs in a down market.


September 29 • 1:21 PM

Conference Call: Free Will Conference


September 29 • 12:00 PM

How Copyright Law Protects Art From Criticism

A case for allowing the copyright on Gone With the Wind to expire.


September 29 • 10:00 AM

Should We Be Told Who Funds Political Attack Ads?

On the value of campaign finance disclosure.


September 29 • 8:00 AM

Searching for a Man Named Penis

A quest to track down a real Penis proves difficult.


September 29 • 6:00 AM

Why Do So Many People Watch HGTV?

The same reason so many people watch NCIS or Law and Order: It’s all a procedural.


September 29 • 4:00 AM

The Link Between Depression and Terrorism

A new study from the United Kingdom finds a connection between depression and radicalization.


September 26 • 4:00 PM

Fast Track to a Spill?

Oil pipeline projects across America are speeding forward without environmental review.


September 26 • 2:00 PM

Why Liberals Love the Disease Theory of Addiction, by a Liberal Who Hates It

The disease model is convenient to liberals because it spares them having to say negative things about poor communities. But this conception of addiction harms the very people we wish to help.


September 26 • 1:21 PM

Race, Trust, and Split-Second Judgments


September 26 • 9:47 AM

Dopamine Might Be Behind Impulsive Behavior

A monkey study suggests the brain chemical makes what’s new and different more attractive.


September 26 • 8:00 AM

A Letter Becomes a Book Becomes a Play

Sarah Ruhl’s Dear Elizabeth: A Play in Letters From Elizabeth Bishop to Robert Lowell and Back Again takes 900 pages of correspondence between the two poets and turns them into an on-stage performance.


September 26 • 7:00 AM

Sonic Hedgehog, DICER, and the Problem With Naming Genes

Wait, why is there a Pokemon gene?


Follow us


Mysterious Resting State Networks Might Be What Allow Different Brain Therapies to Work

Deep brain stimulation and similar treatments target the hubs of larger resting-state networks in the brain, researchers find.

Trust Is Waning, and Inequality May Be to Blame

Trust in others and confidence in institutions is declining, while economic inequality creeps up, a new study shows.

Dopamine Might Be Behind Impulsive Behavior

A monkey study suggests the brain chemical makes what's new and different more attractive.

School Counselors Do More Than You’d Think

Adding just one counselor to a school has an enormous impact on discipline and test scores, according to a new study.

How a Second Language Trains Your Brain for Math

Second languages strengthen the brain's executive control circuits, with benefits beyond words.

The Big One

One company, Amazon, controls 67 percent of the e-book market in the United States—down from 90 percent five years ago. September/October 2014 new-big-one-5

Copyright © 2014 by Pacific Standard and The Miller-McCune Center for Research, Media, and Public Policy. All Rights Reserved.